PathAI announced that AIM-MASH AI Assist has received qualification from the European Medicines Agency (EMA), making it the first and only AI-assisted pathology tool approved for histology enrollment and endpoint assessment in MASH clinical trials. This recognition confirms its scientific validity for regulatory decision-making, reinforcing AI’s role in improving trial efficiency, diagnostic consistency, and therapy development for metabolic dysfunction-associated steatohepatitis (MASH). Full release here and below.

AIM-MASH AI Assist delivers accurate, consistent, and scalable pathology assessments, ensuring more reliable trial data to accelerate treatment development. By enabling a single central pathologist to score liver biopsies, it reduces reliance on multi-reader consensus and enhances efficiency in patient selection and monitoring.

Key Highlights:

• First and only EMA-qualified AI pathology tool for histology enrollment and endpoint assessment in MASH trials.
• Supports single central pathologist scoring, reducing reliance on multi-reader consensus.
  Facilitates patient evaluation for Phase 2 and 3 MASH clinical trials.
• Fully validated for accuracy and reliability, ensuring high-quality assessments.
• Deployed on the AISight Clinical Trials Platform, offering a secure and efficient environment for implementation.

This milestone marks a significant advancement in the use of AI to support MASH clinical trials and accelerate the development of new therapies. If interested, I’d be happy to connect you with Andy Beck, MD, PhD, CEO and co-founder of PathAI, to discuss the impact of AIM-MASH AI Assist and what this EMA qualification means for the future of AI-driven pathology.